Geneva, Switzerland, July 20, 2022 – 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), announced today the publication in the leading scientific journal “Annals of Neurology” of the results of the collaboration between GeNeuro and the National Institute of Neurological Disorders and Stroke (NINDS). NINDS is part of the National Institutes of Health (NIH) of the United States. This publication describes the novel pathogenic mechanism of HERV-K in sporadic ALS and confirms the action of GeNeuro’s antibody to neutralize this toxicity.
https://geneuro.com/data/news/GeNeuro-PR-publication-SLA-EN-vf.pdf